|
|||||
|
|
A Phase 2b randomized trial of lorecivivint,a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis |
|
| Authors: | Y. Yazici T.E. McAlindon A. Gibofsky N.E. Lane C. Lattermann N. Skrepnik C.J. Swearingen I. Simsek H. Ghandehari A. DiFrancesco J. Gibbs J.R.S. Tambiah M.C. Hochberg |
| Affiliation: | 2. Samumed, LLC, San Diego, CA, USA;3. New York University School of Medicine, New York, NY, USA;4. Tufts Medical Center, Boston, MA, USA;6. Weill Cornell Medical College, New York, NY, USA;5. University of California Davis Medical School, Burlingame, CA, USA;11. Tucson Orthopaedic Institute, Tucson, AZ, USA;12. University of Maryland, College Park, MD, USA |
| Abstract: | |
| Keywords: | Clinical trial Wnt pathway Patient-reported outcomes CLK2 DYRK1A Knee pain |
| 本文献已被 ScienceDirect 等数据库收录！ | |
